- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05105841
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
A Phase 2 Study of the Safety and Efficacy of Venetoclax in Combination With Obinutuzumab or Ibrutinib in Japanese Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, representing approximately 30% of all adult leukemias. There is a large difference in proportion of malignant lymphoma between the United States (US) and Japan was seen in CLL/small lymphocytic lymphoma (SLL) (Japan, 3.2%; US, 24.1%). The purpose of this study is to assess how well venetoclax works in combination with obinutuzumab (V+G, Cohort 1) or with ibrutinib (V+I, Cohort 2) in Japanese participants with previously untreated CLL/Small Lymphocytic Lymphoma (SLL). Adverse events and change in disease activity will be assessed.
Venetoclax is an approved drug for the treatment of CLL and SLL. Study doctors put the participants in 1 of 2 groups, called treatment arms, based on variable alternating assignment. Approximately 20 adult participants with previously untreated CLL/SLL will be enrolled in the study in approximately 20 sites in Japan.
Participants in group 1 will receive oral venetoclax + intravenous (IV) obinutuzumab (V+G) in 28-day cycles for a total of 12 cycles, and participants in group 2 will receive oral venetoclax + oral ibrutinib (V+I) in 28-day cycles for a total of 15 cycles.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Expanded Access
Contacts and Locations
Study Locations
-
-
Aichi
-
Nagoya-shi, Aichi, Japan, 460-0001
- NHO Nagoya Medical Center /ID# 233523
-
Nagoya-shi, Aichi, Japan, 464-8681
- Aichi Cancer Center Hospital /ID# 238797
-
Nagoya-shi, Aichi, Japan, 466-8650
- Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 233524
-
-
Chiba
-
Chiba-shi, Chiba, Japan, 260-8717
- Chiba Cancer Center /ID# 238839
-
-
Ehime
-
Matsuyama-shi, Ehime, Japan, 791-0280
- National Hospital Organization Shikoku Cancer Center /ID# 234059
-
-
Fukuoka
-
Fukuoka-shi, Fukuoka, Japan, 812-8582
- Kyushu University Hospital /ID# 238437
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan, 060-8648
- Hokkaido University Hospital /ID# 238377
-
-
Hyogo
-
Amagasaki-shi, Hyogo, Japan, 660-8550
- Hyogo Prefectural Amagasaki General Medical Center /ID# 234082
-
-
Kanagawa
-
Isehara-shi, Kanagawa, Japan, 259-1193
- Tokai University Hospital /ID# 238970
-
-
Kyoto
-
Kyoto-shi, Kyoto, Japan, 602-8566
- University Hospital Kyoto Prefectural University of Medicine /ID# 239883
-
-
Miyagi
-
Sendai-shi, Miyagi, Japan, 9808574
- Tohoku University Hospital /ID# 238433
-
-
Niigata
-
Niigata-shi, Niigata, Japan, 951-8520
- Niigata University Medical & Dental Hospital /ID# 238324
-
-
Okayama
-
Okayama-shi, Okayama, Japan, 700-8558
- Okayama University Hospital /ID# 238467
-
-
Osaka
-
Osakasayama-shi, Osaka, Japan, 589-8511
- Kindai University Hospital /ID# 234001
-
Suita-shi, Osaka, Japan, 565-0871
- Osaka University Hospital /ID# 234037
-
-
Shimane
-
Izumo-shi, Shimane, Japan, 693-8501
- Shimane University Hospital /ID# 234076
-
-
Tochigi
-
Shimotsuke-shi, Tochigi, Japan, 329-0498
- Jichi Medical University Hospital /ID# 238434
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan, 104-0045
- National Cancer Center Hospital /ID# 232449
-
Koto-ku, Tokyo, Japan, 135-8550
- The Cancer Institute Hospital Of JFCR /ID# 232450
-
-
Yamagata
-
Yamagata-shi, Yamagata, Japan, 990-9585
- Yamagata University Hospital /ID# 234032
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Adult male or female, at least ≥ 65 years old; or 20 to 64 years old and have at least 1 of the following:
- Cumulative Illness Rating Scale (CIRS) score > 6.
- Creatinine clearance (CrCl) estimated < 70 mL/min using Cockcroft-Gault equation.
- Must have measurable nodal disease (by computed tomography [CT]), defined as at least one lymph node > 1.5 cm in longest diameter.
- Diagnosed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) that requires treatment according to the Modified 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria.
Exclusion Criteria:
- Transformation of Chronic Lymphocytic Leukemia (CLL) to aggressive non-Hodgkin lymphoma (NHL; Richter's transformation or pro-lymphocytic leukemia).
- Previous treatment history for CLL/SLL.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Venetoclax + Obinutuzumab (V+G)
Participants will receive venetoclax + obinutuzumab for twelve 28-day cycles.
|
Oral Tablet
Other Names:
Intravenous (IV) Infusion
Other Names:
|
Experimental: Venetoclax + Ibrutinib (V+I)
Participants will receive venetoclax + ibrutinib for fifteen 28-day cycles.
|
Oral Tablet
Other Names:
Oral Capsule
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Remission (CR) with an Incomplete Marrow Recovery (CRi) Rate, as Assessed by an Independent Review Committee (IRC) per Modified 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) for Venetoclax + Obinutuzumab (V+G)
Time Frame: Up to Week 32
|
CR rate is defined as the percentage of participants achieving a best response of CR or CRi.
|
Up to Week 32
|
CR/CRi Rate, as Assessed by an IRC per iwCLL for Venetoclax + Ibrutinib (V+I)
Time Frame: Up to Week 56
|
CR rate is defined as the percentage of participants achieving a best response of CR or CRi.
|
Up to Week 56
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CR/CRi Rate, as Assessed by an Investigator per iwCLL for (V+G)
Time Frame: Up to Week 32
|
CR rate is defined as the percentage of participants achieving a best response of CR or CRi.
|
Up to Week 32
|
CR/CRi Rate, as Assessed by an Investigator per iwCLL for (V+I)
Time Frame: Up to Week 56
|
CR rate is defined as the percentage of participants achieving a best response of CR or CRi.
|
Up to Week 56
|
Overall response rate (ORR) as Assessed by IRC for (V+G)
Time Frame: Up to Week 32
|
ORR is defined as the proportion of participants with a best overall response of CR, CRi, partial remission (PR) or nodular partial remission (nPR) per 2008 iwCLL criteria as assessed by an IRC.
|
Up to Week 32
|
ORR as Assessed by IRC (V+I)
Time Frame: Up to Week 56
|
ORR is defined as the proportion of participants with a best overall response of CR, CRi, partial remission (PR) or nodular partial remission (nPR) per 2008 iwCLL criteria as assessed by an IRC.
|
Up to Week 56
|
ORR as Assessed by Investigator for (V+G)
Time Frame: Up to Week 32
|
ORR is defined as the proportion of participants with a best overall response of CR, CRi, partial remission (PR) or nodular partial remission (nPR) per 2008 iwCLL criteria as assessed by an investigator.
|
Up to Week 32
|
ORR Assessed by Investigator + Ibrutinib (V+I)
Time Frame: Up to Week 56
|
ORR is defined as the proportion of participants with a best overall response of CR, CRi, partial remission (PR) or nodular partial remission (nPR) per 2008 iwCLL criteria as assessed by an investigator.
|
Up to Week 56
|
Progression-Free Survival (PFS) as Assessed by IRC for (V+G)
Time Frame: Up to Week 32
|
PFS is defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurs first, as determined by an IRC according to iwCLL criteria.
|
Up to Week 32
|
PFS as Assessed by IRC for (V+I)
Time Frame: Up to Week 56
|
PFS is defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurs first, as determined by an IRC according to iwCLL criteria.
|
Up to Week 56
|
PFS as Assessed by Investigator for (V+G)
Time Frame: Up to Week 32
|
PFS is defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurs first, as determined by an investigator according to iwCLL criteria.
|
Up to Week 32
|
PFS as Assessed by Investigator for (V+I)
Time Frame: Up to Week 56
|
PFS is defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurs first, as determined by an investigator according to iwCLL criteria.
|
Up to Week 56
|
Duration of response (DOR) as Assessed by IRC for (V+G)
Time Frame: Up to Week 32
|
DOR is defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurs first, as determined by an IRC according to iwCLL criteria.
|
Up to Week 32
|
DOR as Assessed by IRC for (V+I)
Time Frame: Up to Week 56
|
DOR is defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurs first, as determined by an IRC according to iwCLL criteria.
|
Up to Week 56
|
DOR as Assessed by Investigator for (V+G)
Time Frame: Up to Week 32
|
DOR is defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurs first, as determined by an investigator according to iwCLL criteria.
|
Up to Week 32
|
DOR as Assessed by Investigator for (V+I)
Time Frame: Up to Week 56
|
DOR is defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurs first, as determined by an investigator according to iwCLL criteria.
|
Up to Week 56
|
Overall Survival (OS) for (V+G)
Time Frame: Up to Week 32
|
OS is defined as the time from the date of the first dose of any study drug until death due to any cause.
|
Up to Week 32
|
OS for (V+I)
Time Frame: Up to Week 56
|
OS is defined as the time from the date of the first dose of any study drug until death due to any cause.
|
Up to Week 56
|
Time to progression (TTP) as Assessed by IRC for (V+G)
Time Frame: Up to Week 32
|
TTP is defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an IRC according to iwCLL criteria.
|
Up to Week 32
|
TTP as Assessed by IRC for (V+I)
Time Frame: Up to Week 56
|
TTP is defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an IRC according to iwCLL criteria.
|
Up to Week 56
|
TTP as Assessed by Investigator for (V+G)
Time Frame: Up to Week 32
|
TTP is defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an investigator according to iwCLL criteria.
|
Up to Week 32
|
TTP as Assessed by Investigator for (V+I)
Time Frame: Up to Week 56
|
TTP is defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an investigator according to iwCLL criteria.
|
Up to Week 56
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: ABBVIE INC., AbbVie
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Leukemia, B-Cell
- Chronic Disease
- Lymphoma
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Venetoclax
- Obinutuzumab
Other Study ID Numbers
- M20-353
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia (CLL)
-
AbbVieRecruitingCancer, Chronic Lymphocytic Leukemia (CLL)Korea, Republic of
-
Hackensack Meridian HealthCelgene CorporationTerminatedSmall Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia(CLL)United States
-
Piramal Enterprises LimitedDana-Farber Cancer Institute; Norris Cotton Cancer CenterSuspendedRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL)United States
-
Virginia Commonwealth UniversityGilead SciencesWithdrawnChronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
-
Tampere University HospitalCompleted
-
AstraZenecaRecruitingChronic Lymphocytic Leukaemia (CLL)Germany
-
University of California, IrvineUnited States Department of DefenseActive, not recruitingAcute Myeloid Leukemia | Chronic Lymphocytic Leukemia | AML, Adult | CLL | CLL, Relapsed | CLL, RefractoryUnited States
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.WithdrawnChronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | CLL/SLL | SLLUnited States
-
Novartis PharmaceuticalsCompletedChronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, ChronicUnited States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
-
AstraZenecaCLL ConsortiumCompletedB Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)United States
Clinical Trials on Venetoclax
-
Virginia Commonwealth UniversityAbbVieWithdrawnRelapsed Small Cell Lung Cancer | Refractory Small Cell Lung Carcinoma
-
University of Maryland, BaltimoreActive, not recruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States
-
Yale UniversityCompleted
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic CLL Study GroupActive, not recruitingChronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in RemissionNetherlands, Belgium, Denmark, Finland, Norway, Sweden
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic Lymphoma GroupActive, not recruiting
-
The Lymphoma Academic Research OrganisationInstitute of Cancer Research, United KingdomRecruitingMantle Cell LymphomaFrance, United Kingdom, Belgium
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingChronic Lymphocytic LeukemiaUnited States
-
BioSight Ltd.Recruiting